BMYBristol-Myers SquibbFinished
A Study of Relatlimab Plus Nivolumab in Combination With Chemotherapy vs. Nivolumab in Combination With Chemotherapy as First Line Treatment for Participants With Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC)
Non-small Cell Lung Cancer · Recurrent Non-small Cell Lung Cancer · Metastatic Non-small Cell Lung Cancer
3Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +2.6
2 insiders sold shares within a month
Since Sep 9, 2026 · was worth 5, fading over time
Worry score3
Score over time
- Stage
- Phase 2
- Patients
- 468 (final count)
- Started
- Feb 17, 2021
- Main results expected
- Jan 11, 2024
- Fully finished
- May 6, 2026
- Results posted
- Mar 18, 2025
What counts as success
The trial's main goal(s), called the “primary outcome.”
TRAEs Leading to Discontinuation Within 12 Weeks of First Dose in Part 1
Measured over: from first dose to 12 weeks after first dose
ORR Per RECISTS v1.1 by BICR in Part 2
Measured over: Approximately 14.8 Months
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- insider_selling_cluster: base 5, now 2.6, since 2026-09-09, fades (half-life)
Raw record changes
- none yet
Trial ID NCT04623775 · record last updated 2026-06-18 · checked 2026-11-09 15:47 UTC